# Golidocitinib With PD-1 Inhibitors as Maintenance Treatment for Previously Untreated ES-SCLC

Source: https://onco.cc/trials/nct07110103/  
OnCo record `nct07110103` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of golidocitinib in lung cancer, run by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, now recruiting.

## Summary

Golidocitinib With PD-1 Inhibitors as Maintenance Treatment for Previously Untreated ES-SCLC is a phase 2, interventional study registered as NCT07110103 by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, with a registry enrolment figure of 20 participants, started 2025-10-31 and due to reach its primary completion in 2027-03-31. Interventions recorded: golidocitinib with PD-1 inhibitors. Conditions listed: SCLC; SCLC, Extensive Stage. Primary outcome: Progression-Free Survival (PFS). Lung eligibility wording from the registry: "Histologically or cytologically confirmed ES-SCLC (stage IV \[any T stage, any N stage, M1 a/b/c stage\] according to the 8th edition of the AJCC TNM staging system for lung cancer, or T3-4 stage disease caused by multiple lung nodules and the disease is too diffuse, or the tumor/nodule volume is to". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-25
- Also known as: JACKPOT38
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT07110103
- Phase: 2
- Setting: Golidocitinib With PD-1 Inhibitors as Maintenance Treatment in Patients With Previously Untreated Extensive-stage Small Cell Lung Cancer: an Open-label, Single-arm, Phase 2 Study
- Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Enrolled: 20

## Sources

- ClinicalTrials.gov NCT07110103: https://clinicaltrials.gov/study/NCT07110103

## Connected records

- cancers: [Extensive-stage small-cell lung cancer](https://onco.cc/cancers/extensive-stage-sclc/)
- drugs: [Golidocitinib](https://onco.cc/drugs/golidocitinib/)
- companies: [Dizal Pharmaceutical](https://onco.cc/companies/dizal/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07110103.json